← Back to Screener
Inventiva S.A. American Depository Shares (IVA)
Price$5.59
Favorite Metrics
Price vs S&P 500 (26W)10.63%
Price vs S&P 500 (4W)-16.05%
Market Capitalization$1.18B
All Metrics
Book Value / Share (Quarterly)$1.27
P/TBV (Annual)4.56x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-28.33%
Cash Flow / Share (Quarterly)$-1.19
Price vs S&P 500 (YTD)17.80%
Net Profit Margin (TTM)-7899.55%
EPS (TTM)$-2.70
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-2.70
Revenue Growth (5Y)64.51%
EPS (Annual)$-2.23
ROI (Annual)-67.94%
Net Profit Margin (5Y Avg)-2432.66%
Cash / Share (Quarterly)$1.03
Revenue Growth QoQ (YoY)-99.68%
ROA (Last FY)-154.84%
Revenue Growth TTM (YoY)-51.26%
EBITD / Share (TTM)$-0.82
ROE (5Y Avg)-66.60%
Operating Margin (TTM)-3145.51%
Cash Flow / Share (Annual)$-1.06
P/B Ratio21.99x
P/B Ratio (Quarterly)4.50x
Net Income / Employee (Annual)$-5
EV / Revenue (TTM)77.72x
Net Interest Coverage (TTM)-0.66x
ROA (TTM)-208.80%
EPS Incl Extra (Annual)$-2.23
Current Ratio (Annual)0.92x
Quick Ratio (Quarterly)2.91x
3-Month Avg Trading Volume0.38M
52-Week Price Return51.11%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.26
P/S Ratio (Annual)223.23x
Asset Turnover (Annual)0.08x
52-Week High$6.20
Operating Margin (5Y Avg)-1301.07%
EPS Excl Extra (Annual)$-2.23
CapEx CAGR (5Y)19.61%
Tangible BV CAGR (5Y)-5.66%
26-Week Price Return19.38%
Quick Ratio (Annual)0.90x
13-Week Price Return-16.37%
Total Debt / Equity (Annual)0.76x
Current Ratio (Quarterly)2.96x
Enterprise Value$1,246.078
Revenue / Share Growth (5Y)16.89%
Asset Turnover (TTM)0.09x
Book Value / Share Growth (5Y)-22.11%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-7891.26%
Cash / Share (Annual)$1.19
3-Month Return Std Dev53.40%
Net Income / Employee (TTM)$-5
ROE (Last FY)-119.35%
Net Interest Coverage (Annual)-0.60x
EPS Basic Excl Extra (Annual)$-2.23
Receivables Turnover (TTM)2.35x
Total Debt / Equity (Quarterly)0.76x
EPS Incl Extra (TTM)$-2.70
Receivables Turnover (Annual)4.24x
ROI (TTM)-99.63%
P/S Ratio (TTM)223.23x
Pretax Margin (5Y Avg)-2424.93%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$1.26
Price vs S&P 500 (52W)16.01%
Year-to-Date Return21.04%
5-Day Price Return9.52%
EPS Normalized (Annual)$-2.23
ROA (5Y Avg)-85.05%
Net Profit Margin (Annual)-7899.55%
Month-to-Date Return0.53%
Cash Flow / Share (TTM)$-2.20
EBITD / Share (Annual)$-0.89
Operating Margin (Annual)-3145.51%
LT Debt / Equity (Annual)0.56x
ROI (5Y Avg)-54.61%
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$-2.70
P/TBV (Quarterly)4.56x
P/B Ratio (Annual)4.50x
Pretax Margin (TTM)-7891.26%
Book Value / Share (Annual)$1.27
Price vs S&P 500 (13W)-19.24%
Beta0.30x
Revenue / Share (TTM)$0.02
ROE (TTM)-145.38%
52-Week Low$2.56
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IVAInventiva S.A. American Depository Shares | 223.23x | -51.26% | — | — | $5.59 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Inventiva SA is a French biopharmaceutical company developing drug candidates targeting nuclear receptors and epigenetic pathways. Its lead program, lanifibranor, is being advanced for non-alcoholic steatohepatitis (NASH), a disease with no currently approved treatments, representing a significant commercial opportunity. The company maintains a pre-clinical pipeline in oncology, fibrosis, and rare diseases, and generates revenue through research partnerships with major pharmaceutical partners including AbbVie and BI.